logo
Share SHARE
FONT-SIZE Plus   Neg

GlaxoSmithKline, Theravance Say Lung Disease Treatment Showed Positive Results

British drug giant GlaxoSmithKline Plc (GSK, GSK.L) and US biopharma firm Theravance Inc. (THRX) Monday said that four pivotal phase III studies of their investigational combination drug showed statistically significant improvements in patients with chronic obstructive pulmonary disease, or COPD.

Once-daily LAMA/LABA is a combination of two investigational bronchodilator molecules, which GlaxoSmithKline is developing with Theravance. Subject to successful completion of the ongoing studies, the companies plan to commence global regulatory filings from the end of this year.

GlaxoSmithKline said the studies involved over 4,000 patients with COPD, which had two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo. The two 24-week active comparator studies compared the combination with the LAMA, long-acting muscarinic antagonist, tiotropium - a widely prescribed maintenance bronchodilator for COPD.

The first 24-week study involved 1,493 patients and the second 24-week study randomised 1,536 patients. Both showed statistically significant improvements.

In active comparator efficacy studies, the first 24-week study randomised 846 patients and the second 24-week study randomised 872 patients. These studies also resulted in a statistically significant improvement in patients with COPD.

COPD makes breathing difficult and is mainly caused by smoking all though it occurs in non-smokers too. According to reports, more than 12 million American adults suffer from COPD, and another 12 million Americans likely have this lung disease without knowing it.

GSK.L is currently trading at 1,449 pence, up 2 pence or 0.14 percent, on a volume of 1.91 million shares o the LSE. In US, GSK closed Friday's regular trading at $45.57 om the NYSE.

THRX ended on Friday at $22.22 on the Nasdaq.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
World's largest oil company Saudi Aramco's initial public offering is on track and the listing will be in the second half of 2018, CEO Amin Nasser said in an exclusive interview with CNBC. There have been reports that the much awaited IPO might be delayed by one year. Taco Bell, the Mexican fast food chain of Yum! Brands Inc., is reportedly testing a new dessert product called the "Kit Kat Chocoladilla" at select locations in Wisconsin. It was tested last year in the UK. Nick Caporella, the chief executive officer of National Beverage Corp., has lashed out at short sellers after his company's shares declined more than 22 percent this month from their September 11 peak. In a statement, Caporella noted that less than 15 percent of the daily volume traded on major exchanges is financially driven by company fundamentals.
comments powered by Disqus
Follow RTT